EP1162954A1 - Novel formulations comprising lipid-regulating agents - Google Patents

Novel formulations comprising lipid-regulating agents

Info

Publication number
EP1162954A1
EP1162954A1 EP00919545A EP00919545A EP1162954A1 EP 1162954 A1 EP1162954 A1 EP 1162954A1 EP 00919545 A EP00919545 A EP 00919545A EP 00919545 A EP00919545 A EP 00919545A EP 1162954 A1 EP1162954 A1 EP 1162954A1
Authority
EP
European Patent Office
Prior art keywords
oil
composition
lipid
fatty acid
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00919545A
Other languages
German (de)
French (fr)
Inventor
Jitendra P. Patel
Yeshwant D. Sanzgiri
John M. Lipari
Thomas L. Reiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP1162954A1 publication Critical patent/EP1162954A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention relates to novel formulations comprising lipid-regulating agents.
  • 2- [4- (4-chlorobenzoyl) phenoxy] -2 -methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
  • Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726.
  • U.S. Patent No. 4,895,726 discloses a co- micronized formulation of fenofibrate and a solid surfactant.
  • U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix.
  • the formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
  • EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granulate thus produced is dried.
  • PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch.
  • the neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
  • U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon.
  • the carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
  • Gemfibrozil is another member of the fibrate class of lipid-regulating agents.
  • U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach.
  • the first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative
  • the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth) acrylate copolymer prior to admixture with the first granulation.
  • the first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.
  • U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid- disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
  • statins Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members.
  • U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder) , one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
  • fillers such as lactose and/or microcrystalline cellulose
  • binders such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder)
  • disintegrating agents such as cro
  • the present invention is directed to a formulation comprising a lipid-regulating agent dissolved in an oil, with subsequent emulsification using one or more emulsifiers.
  • This formulation forms fine and stable emulsions.
  • the emulsions result in an increase in drug solubility, oral bioavailability and half-life.
  • the formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art.
  • Figure 1 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 1 and a reference compound .
  • the bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.
  • the solution comprising the lipid-regulating agent is prepared by dissolving said agent in the oil with adequate mixing.
  • An emulsifier or emulsifier blend is added to said mixture and mixed until uniform. If desired, water can be then added to the resulting mixture with agitation to form a uniform emulsion.
  • the delivery system of the present invention results in increased solubility, half-life and bioavailability of the lipid-regulating agent. It can be further diluted with additional liquids or it may be thickened and/or stabilized with various pharmaceutical excipients to vary its existing properties .
  • Suitable oils include, but are not limited to, any pharmaceutically acceptable oil, such as, for example, soybean oil, coconut oil, canola oil, corn oil, palm kernel oil, cottonseed oil, olive oil, peanut oil, safflower oil and sesame oil.
  • Suitable emulsifiers include any pharmaceutically acceptable hydrophilic or lipophilic emulsifier or combinations thereof, such as, for example, phospholipids, polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives, polyoxyl -35 -castor oil (Cremophor EL, available from BASF) , castor oil or hydrogenated castor oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene- polyoxypropylene co-polymers and block co-polymers, and TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) .
  • Preferred emulsifiers include polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil (Cremophor EL, available from BASF) .
  • antioxidants such as, for example, tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, etc.
  • pH stabilizers such as, for example, citric acid, tartaric acid, fumaric acid, acetic acid, glycine, arginine, lysine, potassium hydrogen phosphate, etc.
  • thickeners/suspending agents such as, for example, hydrogenated vegetable oils, beeswax, colloidal silicon dioxide, gums, celluloses, silicates, bentonite, etc.
  • flavoring agents such as, for example, cherry, lemon, aniseed flavors, etc.
  • sweeteners such as, for example, aspartame, saccharin, cyclamates, etc.
  • co-solvents such as, for example, ethanol
  • the resulting liquid comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into soft or hard shells or capsules for oral administration, or delivered by some other means obvious to those skilled in the art.
  • the said liquid can be used to improve the oral bioavailability, and increase the half-life and solubility of said lipid-regulating agent.
  • SR Soybean oil 24 g is added to a beaker and pravastatin (1 g) is dispersed in it by stirring.
  • Sorbitan monooleate 2.5 g is added to the beaker and mixed until uniform.
  • Polysorbate 80 0.5 g is then added and mixed until uniform.
  • water 72 g is added slowly with constant mixing until a uniform emulsion resulted.
  • SR Soybean oil 24 g is added to a beaker and atorvastatin (1 g) is dispersed in it by stirring.
  • Sorbitan monooleate 2.5 g is added to the beaker and mixed until uniform.
  • Polysorbate 80 0.5 g is then added and mixed until uniform.
  • water 72 g is added slowly with constant mixing until a uniform emulsion resulted.
  • the plasma concentrations of fenofibric acid were determined by HPLC. Concentrations were normalized to a 6.7 mg/kg dose in each dog.
  • Figure 1 presents the resulting data in graph form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium.

Description

Novel Formulations Comprising Lipid-Regulating Agents
Field of the Invention
The present invention relates to novel formulations comprising lipid-regulating agents.
Background of the Invention
2- [4- (4-chlorobenzoyl) phenoxy] -2 -methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726. U.S. Patent No. 4,895,726 discloses a co- micronized formulation of fenofibrate and a solid surfactant.
U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed. European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granulate thus produced is dried.
PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon. The carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
Gemfibrozil is another member of the fibrate class of lipid-regulating agents. U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach. The first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative, and the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth) acrylate copolymer prior to admixture with the first granulation. The first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.
U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid- disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members. U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder) , one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
It is an object of the present invention to provide formulations of lipid-regulating agents having enhanced bioavailability and longer half-life when compared to commercially available formulations. Summary of the Invention
The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in an oil, with subsequent emulsification using one or more emulsifiers. This formulation forms fine and stable emulsions. The emulsions result in an increase in drug solubility, oral bioavailability and half-life.
The formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art.
Brief Description of the Drawings
Figure 1 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 1 and a reference compound .
Detailed Description of the Invention
The bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.
The solution comprising the lipid-regulating agent is prepared by dissolving said agent in the oil with adequate mixing. An emulsifier or emulsifier blend is added to said mixture and mixed until uniform. If desired, water can be then added to the resulting mixture with agitation to form a uniform emulsion.
The delivery system of the present invention results in increased solubility, half-life and bioavailability of the lipid-regulating agent. It can be further diluted with additional liquids or it may be thickened and/or stabilized with various pharmaceutical excipients to vary its existing properties .
Suitable oils include, but are not limited to, any pharmaceutically acceptable oil, such as, for example, soybean oil, coconut oil, canola oil, corn oil, palm kernel oil, cottonseed oil, olive oil, peanut oil, safflower oil and sesame oil.
Suitable emulsifiers include any pharmaceutically acceptable hydrophilic or lipophilic emulsifier or combinations thereof, such as, for example, phospholipids, polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives, polyoxyl -35 -castor oil (Cremophor EL, available from BASF) , castor oil or hydrogenated castor oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene- polyoxypropylene co-polymers and block co-polymers, and TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) . Preferred emulsifiers include polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil (Cremophor EL, available from BASF) .
Other optional ingredients which may be included in the compositions of the present invention are those which are conventionally used in oil-based drug delivery systems, e.g. antioxidants such as, for example, tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, etc.; pH stabilizers such as, for example, citric acid, tartaric acid, fumaric acid, acetic acid, glycine, arginine, lysine, potassium hydrogen phosphate, etc.; thickeners/suspending agents such as, for example, hydrogenated vegetable oils, beeswax, colloidal silicon dioxide, gums, celluloses, silicates, bentonite, etc.; flavoring agents such as, for example, cherry, lemon, aniseed flavors, etc.; sweeteners such as, for example, aspartame, saccharin, cyclamates, etc.; and co-solvents, such as, for example, ethanol, propylene glycol, polyethylene glycol, dimethyl isosorbide, etc.
The resulting liquid comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into soft or hard shells or capsules for oral administration, or delivered by some other means obvious to those skilled in the art. The said liquid can be used to improve the oral bioavailability, and increase the half-life and solubility of said lipid-regulating agent.
The invention will be understood more clearly from the following non-limiting representative examples:
Example 1
SR Soybean oil (24.33 g) was added to a beaker and fenofibrate (0.67 g) was dissolved in it by stirring. Sorbitan monooleate (2.5 g) was added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) was then added and mixed until uniform. Finally water (72 g) was added slowly with constant mixing until a uniform emulsion resulted. Example 2
SR Soybean oil (24 g) is added to a beaker and pravastatin (1 g) is dispersed in it by stirring. Sorbitan monooleate (2.5 g) is added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) is then added and mixed until uniform. Finally water (72 g) is added slowly with constant mixing until a uniform emulsion resulted.
Example 3
SR Soybean oil (24 g) is added to a beaker and atorvastatin (1 g) is dispersed in it by stirring. Sorbitan monooleate (2.5 g) is added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) is then added and mixed until uniform. Finally water (72 g) is added slowly with constant mixing until a uniform emulsion resulted.
Example 4
The emulsion prepared by the process described in Example 1, and from a commercial fenofibrate composition, Lipanthyl 67M (Groupe Fournier) (Reference) , were administered to a group of dogs at a dose of 67 mg fenofibrate/dog (10 mL emulsion or one capsule/dog) . The plasma concentrations of fenofibric acid were determined by HPLC. Concentrations were normalized to a 6.7 mg/kg dose in each dog. Figure 1 presents the resulting data in graph form. The results provided as mean ± SD, n=6, were as follows : Lipanthyl 67M (Reference) : Cmax = 1.88 ± 0.97 mcg/ml Tmax = 1.6 ± 0.9 hr AUC (0-24) = 11.08 ± 9.42 mcg*hr/ml
Emulsion of Example 1 : Cmax = 4.97 ± 3.13 mcg/ml Tmax = 1.1 ± 0.5 hr
AUC (0-24) = 24.21 ± 11.69 mcg*»hr/ml AUC relative to Reference = 2.2

Claims

Claims
1. A composition comprising a lipid-regulating agent dissolved or dispersed in at least one oil with one or more emulsifiers, wherein the mixture is capable of forming an emulsion upon dilution with an aqueous phase .
2. A composition of claim 1 wherein said lipid-regulating agent is a fibrate.
3. A composition of claim 2 wherein said fibrate is fenofibrate .
4. A composition of claim 1 wherein said lipid-regulating agent is a statin.
5. A composition of claim 4 wherein said statin is pravastatin.
6. A composition of claim 4 wherein said statin is atorvastatin.
7. A composition of claim 1 wherein at least one or more of said emulsifiers is selected from phospholipids, polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives, Polyoxyl-35-castor oil (Cremophor EL, available from BASF) , castor oil or hydrogenated castor oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene-polyoxypropylene co- polymers and block co-polymers, and TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) .
8. A composition of claim 7 wherein at least one or more of said emulsifiers is polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil.
9. A composition of claim 1 wherein said oil is selected from soybean oil, coconut oil, canola oil, corn oil, palm kernel oil, cottonseed oil, olive oil, peanut oil, safflower oil and sesame oil.
10. A composition of claim 9 wherein said oil is soybean oil.
11. A composition of claim 1 further comprising a co- solvent .
12. A composition of claim 11 wherein said co-solvent is ethanol, propylene glycol or polyethylene glycol.
13. A delivery system comprising a composition of claim 1.
14. A delivery system of claim 13 wherein said delivery system is an emulsion.
15. A delivery system of claim 13 wherein said delivery system is a capsule.
16. A method of treating hyperlipidemia comprising the administration of a composition of claim 1 to a patient .
17. A method of treating hyperlipidemia comprising the administration of a composition of claim 3 to a patient .
18. A method of treating hyperlipidemia comprising the administration of a composition of claim 14 to a patient .
EP00919545A 1999-03-31 2000-03-23 Novel formulations comprising lipid-regulating agents Withdrawn EP1162954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28251399A 1999-03-31 1999-03-31
US282513 1999-03-31
PCT/US2000/007650 WO2000057859A1 (en) 1999-03-31 2000-03-23 Novel formulations comprising lipid-regulating agents

Publications (1)

Publication Number Publication Date
EP1162954A1 true EP1162954A1 (en) 2001-12-19

Family

ID=23081844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00919545A Withdrawn EP1162954A1 (en) 1999-03-31 2000-03-23 Novel formulations comprising lipid-regulating agents

Country Status (7)

Country Link
EP (1) EP1162954A1 (en)
JP (1) JP2003520767A (en)
AU (1) AU4021100A (en)
CA (1) CA2365128A1 (en)
HK (1) HK1043936A1 (en)
MX (1) MXPA01009840A (en)
WO (1) WO2000057859A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230253B1 (en) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and their use in the treatment of vascular indications
DK1355644T3 (en) 2001-01-26 2006-10-23 Schering Corp Use of substituted azetidinone compounds for the treatment of sitosterolemia
ATE358477T1 (en) * 2001-06-12 2007-04-15 Galephar M F ORAL MEDICINAL COMPOSITION CONTAINING A STATIN DERIVATIVE
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (en) 2001-09-21 2005-02-10 シェーリング　コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (en) 2003-03-07 2010-12-01 シェーリング コーポレイション Substituted azetidinone compounds, their formulations and uses for the treatment of hypercholesterolemia
JP2006519869A (en) 2003-03-07 2006-08-31 シェーリング　コーポレイション Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
ES2255426B1 (en) 2004-10-19 2007-08-16 Gp Pharm, S.A. PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
MX2008001597A (en) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Novel formulations comprising fenofibrate and a statin, and related methods of treatment.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2400840A4 (en) * 2009-02-24 2012-08-01 Madeira Therapeutics Liquid statin formulations
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
MX346224B (en) * 2011-02-04 2017-03-10 Biocopea Ltd Compostions and methods for treating chronic inflammation and inflammatory diseases.
CN103110594A (en) * 2013-02-02 2013-05-22 台州职业技术学院 Atorvastatin calcium nano freeze-dried powder and preparation method thereof
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1590864A (en) * 1978-05-16 1981-06-10 Lilly Industries Ltd Thixotropic filling medium for hard gelatin capsules
EP0031603A1 (en) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmaceutical composition of matter
EP0231367B1 (en) * 1985-08-02 1991-07-24 Wolf, Horst P.O., Dr. Use of oxirancarboxylic acids for the treatment of hyperlipemia
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0057859A1 *

Also Published As

Publication number Publication date
AU4021100A (en) 2000-10-16
CA2365128A1 (en) 2000-10-05
HK1043936A1 (en) 2002-10-04
MXPA01009840A (en) 2002-06-21
WO2000057859A1 (en) 2000-10-05
JP2003520767A (en) 2003-07-08

Similar Documents

Publication Publication Date Title
EP1162954A1 (en) Novel formulations comprising lipid-regulating agents
US6372251B2 (en) Formulations comprising lipid-regulating agents
WO2000037057A2 (en) Novel formulations comprising lipid-regulating agents
CA2367995A1 (en) Novel formulations comprising lipid-regulating agents
US6465011B2 (en) Formulations comprising lipid-regulating agents
US20020102301A1 (en) Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6838091B2 (en) Formulations comprising lipid-regulating agents
US6719999B2 (en) Formulations comprising lipid-regulating agents
WO2002100394A1 (en) Oral pharmaceutical composition containing a statin derivative
US6814977B1 (en) Formulations comprising lipid-regulating agents
WO2000072829A1 (en) Novel formulations comprising lipid-regulating agents
WO2024033521A1 (en) Oral solid dosage forms comprising cannabinoids
CA3072559A1 (en) Pharmaceutical composition
US20020040046A1 (en) Novel formulations comprising lipid-regulating agents
US7014864B1 (en) Formulations comprising lipid-regulating agents
WO2025172553A1 (en) Oral solid dosage forms comprising cannabinoids
MXPA06005247A (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20010926;SI PAYMENT 20010926

17Q First examination report despatched

Effective date: 20031202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050816

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1043936

Country of ref document: HK